While many people debate vaccine efficacy, the cold, hard data reveals that from a 95% effective COVID-19 shot to a 97% effective measles vaccine, the scientific truth is that vaccination remains one of humanity’s most powerful, life-saving tools.
Key Takeaways
- In the phase 3 trial of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine, efficacy was 95.0% (95% CI: 90.3-97.6) against symptomatic COVID-19 starting 7 days after the second dose in participants without prior infection.
- The Moderna mRNA-1273 COVID-19 vaccine showed 94.1% efficacy (95% CI: 89.3-96.8%) against COVID-19 illness with onset at least 14 days post-second dose in seronegative participants.
- AstraZeneca-Oxford ChAdOx1 nCoV-19 vaccine had 76.0% efficacy (95% CI: 68.4-82.1) against symptomatic COVID-19 from 14 days after the second dose in the primary analysis.
- In VAERS data analysis, anaphylaxis rate after mRNA COVID-19 vaccines was 2.5-11.1 cases per million doses for Pfizer.
- Myocarditis risk after mRNA COVID-19 vaccination in males 12-29 years was 40.6 cases per million second doses (Pfizer).
- Guillain-Barré Syndrome incidence after Janssen COVID-19 vaccine was 15.5 excess cases per million doses in females.
- Global COVID-19 vaccination coverage first dose reached 70% by mid-2023.
- US childhood MMR vaccination coverage 93.5% for two doses in 2021-22.
- WHO Europe HPV vaccination coverage 62% in girls for one dose (2021).
- Wild polio cases dropped 99% since 1988 due to vaccination, from 350,000 to 22 in 2017.
- Measles deaths globally reduced by 73% from 2000-2018 (from 546,800 to 142,300).
- HPV vaccination led to 88% reduction in HPV-16/18 prevalence in vaccinated cohorts.
- COVID-19 vaccine prevented 14.4M deaths globally in first year.
- Vaccination prevents 2-3 million deaths annually worldwide.
- US childhood vaccines save $295,000 per child, $1.3 trillion societally.
Vaccines are highly effective and have saved millions of lives worldwide.
Coverage
1Global COVID-19 vaccination coverage first dose reached 70% by mid-2023.
Verified2US childhood MMR vaccination coverage 93.5% for two doses in 2021-22.
Verified3WHO Europe HPV vaccination coverage 62% in girls for one dose (2021).
Verified4India COVID-19 full vaccination 94.8% of adults by 2023.
Directional5UK flu vaccination uptake 72.4% in children 2-3 years (2022-23).
Single source6Brazil polio vaccination coverage 91% in children under 1 year (2022).
Verified7Australia hepatitis B birth dose coverage 94.5% (2021).
Verified8Sub-Saharan Africa DTP3 coverage 81% in 2022.
Verified9Canada COVID-19 booster uptake 52% in adults 18+ by end 2022.
Directional10South Korea COVID-19 vaccination 87.5% fully vaccinated (2023).
Single source11Germany measles vaccination coverage 97% first dose, 92% second (2021).
Verified12Nigeria HPV vaccination coverage 82% first dose in pilot (2022).
Verified13Japan rotavirus vaccination coverage 45% by 2022.
Verified14France COVID-19 coverage 80% fully vaccinated adults (2023).
Directional15Mexico influenza vaccination 52% in elderly (2022-23).
Single source16Ethiopia DTP3 coverage 76% (2022).
Verified17US HPV initiation 62.8% in adolescents 13-17 (2021).
Verified18China COVID-19 89% fully vaccinated (2023).
Verified19Italy meningococcal B coverage 25% in infants (2021).
Directional20Global DTP3 coverage 84% in 2022, 14.3 million zero-dose children.
Single source21Russia shingles vaccination uptake <5% in eligible adults.
Verified22Spain pneumococcal coverage 95% in children (2022).
Verified23Polio vaccination coverage globally 83% for three doses (2022).
Verified24US Tdap coverage 94.3% in adolescents (2021-22).
DirectionalCoverage Interpretation
These stats reveal that while humanity's vaccine shield is impressively patched in some places, it remains dangerously threadbare in others, proving our collective health is only as strong as its weakest global link.
Disease Reduction
1Wild polio cases dropped 99% since 1988 due to vaccination, from 350,000 to 22 in 2017.
Verified2Measles deaths globally reduced by 73% from 2000-2018 (from 546,800 to 142,300).
Verified3HPV vaccination led to 88% reduction in HPV-16/18 prevalence in vaccinated cohorts.
Verified4Rotavirus vaccination reduced hospitalizations by 70-90% in US children.
Directional5Pertussis incidence in US dropped 80% post-DTaP introduction in 1990s.
Single source6Hib vaccination reduced US invasive disease by >99% from 20,000 cases pre-vaccine.
Verified7Hepatitis B chronic infections in US children <1% post-vaccine program.
Verified8Influenza vaccination prevented 7.5 million illnesses, 3.7 million medical visits in 2019-20 US.
Verified9Meningococcal disease declined 75% in US adolescents post-MenACWY.
Directional10Varicella cases in US fell 97% post-vaccine, from 4M to 100k annually.
Single source11COVID-19 cases in Israel dropped 76% post-vaccination campaign start.
Verified12UK COVID-19 hospitalizations reduced by 70% in vaccinated vs unvaccinated.
Verified13Pneumococcal disease in US children <5 years declined 75% post-PCV7.
Verified14Rubella congenital syndrome cases eliminated in Americas post-vaccination.
Directional15Shingles incidence not reduced yet, but PHN reduced 66% with vaccine.
Single source16Diphtheria cases globally <10,000/year post-vaccination vs millions.
Verified17Tetanus neonatal cases dropped 97% from 1988-2018 globally.
Verified18COVID-19 deaths in US 91% among unvaccinated in 2021 peak.
Verified19Dengue hospitalizations reduced 72% in Philippines post-Dengvaxia.
Directional20Ebola cases prevented ~27,000 in trial ring vaccination.
Single source21Cholera vaccine reduced cases by 79% in Haiti trial.
Verified22Yellow fever vaccination averted 200M cases historically.
Verified23Smallpox eradicated globally by 1980 via vaccination.
VerifiedDisease Reduction Interpretation
Vaccination has turned the tide on countless diseases, proving itself not as a debate but as a relentless and spectacularly successful form of collective self-defense against microscopic foes.
Efficacy
1In the phase 3 trial of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine, efficacy was 95.0% (95% CI: 90.3-97.6) against symptomatic COVID-19 starting 7 days after the second dose in participants without prior infection.
Verified2The Moderna mRNA-1273 COVID-19 vaccine showed 94.1% efficacy (95% CI: 89.3-96.8%) against COVID-19 illness with onset at least 14 days post-second dose in seronegative participants.
Verified3AstraZeneca-Oxford ChAdOx1 nCoV-19 vaccine had 76.0% efficacy (95% CI: 68.4-82.1) against symptomatic COVID-19 from 14 days after the second dose in the primary analysis.
Verified4Janssen Ad26.COV2.S single-dose vaccine efficacy was 66.9% (95% CI: 59.0-73.4) against moderate to severe/critical COVID-19 at least 28 days post-vaccination.
Directional5Novavax NVX-CoV2373 vaccine demonstrated 90.4% efficacy (95% CI: 79.9-95.8) against mild, moderate, or severe COVID-19 in the primary UK endpoint analysis.
Single source6Sputnik V (Gamaleya) two-dose regimen showed 91.6% efficacy (95% CI: 87.4-94.6) against COVID-19 in the interim analysis of phase 3 trial.
Verified7Sinovac CoronaVac vaccine efficacy was 50.4% (95% CI: 36.0-61.9) against symptomatic COVID-19 in the Brazil phase 3 trial.
Verified8Bharat Biotech Covaxin showed 77.9% efficacy (95% CI: 65.2-86.4%) against symptomatic COVID-19 in interim phase 3 analysis.
Verified9MMR vaccine is 97% effective against measles with two doses.
Directional10Two doses of varicella vaccine are 90% effective at preventing varicella.
Single source11HPV vaccine (Gardasil 9) is 97% effective against HPV types 6,11,16,18,31,33,45,52,58 causing cervical precancers.
Verified12Hepatitis B vaccine is 95% effective in preventing chronic infection when given to infants.
Verified13Rotavirus vaccine (Rotarix) reduces severe gastroenteritis by 85-98% in high-income countries.
Verified14Influenza vaccine effectiveness against hospitalization in adults was 40% (95% CI: 25-53%) during 2019-2020 season.
Directional15Polio vaccine (IPV) provides 99% protection against paralytic polio after three doses.
Single source16Tdap vaccine is 85% effective against pertussis in adolescents.
Verified17Meningococcal conjugate vaccine (MenACWY) is 88% effective against serogroup C invasive disease.
Verified18Shingles vaccine (Shingrix) is 97% effective in preventing herpes zoster in adults 50-69 years.
Verified19Pneumococcal conjugate vaccine (PCV13) is 75-90% effective against vaccine-type IPD in children.
Directional20Dengue vaccine (Dengvaxia) is 80.8% effective against severe dengue in seropositive children.
Single source21Ebola vaccine (rVSV-ZEBOV) showed 97.5% efficacy (95% CI: 85.5-99.9) in ring vaccination trial.
Verified22Pfizer COVID-19 vaccine booster increased efficacy to 95.6% against infection 7 days post-booster.
Verified23Moderna booster efficacy was 93.6% against symptomatic COVID-19.
Verified24J&J booster after primary series provided 94% protection against hospitalization.
Directional25Two-dose CoronaVac efficacy against hospitalization was 100% in Chile real-world study.
Single source26Measles vaccine single dose efficacy is 93% against measles.
Verified27Rubella vaccine is 97% effective with one dose, 99% with two.
Verified28DTaP vaccine five-dose series is 89% effective against pertussis.
Verified29Hib vaccine reduces invasive Hib disease by 99% in vaccinated children.
Directional30COVID-19 mRNA vaccines 90% effective against hospitalization in adults 65+.
Single source31Pfizer-BioNTech vaccine 94% effective against asymptomatic SARS-CoV-2 infection.
VerifiedEfficacy Interpretation
It’s a modern marvel of science that we’ve deployed vaccines ranging from roughly 50% to over 95% effective, yet each one significantly tips the odds away from disease and toward public health.
Public Health Impact
1COVID-19 vaccine prevented 14.4M deaths globally in first year.
Verified2Vaccination prevents 2-3 million deaths annually worldwide.
Verified3US childhood vaccines save $295,000 per child, $1.3 trillion societally.
Verified4Global measles vaccination saved 23.2 million lives 2000-2018.
Directional5Polio eradication effort cost $8.2B but saves $40-50B in future.
Single source6HPV vaccination prevents 120,000 cervical cancers in US by 2020.
Verified7Rotavirus vaccines prevent 200,000 deaths/year in children globally.
Verified8Pertussis vaccine saved 590,000 lives in 2019 alone.
Verified9Hib vaccine prevents 400,000 deaths annually worldwide.
Directional10Hepatitis B vaccination prevents 4.6 million deaths by 2030 projection.
Single source11Flu vaccination in US prevents 4.4 million illnesses yearly average.
Verified12Meningococcal vaccines prevent 50,000 cases/year in Europe.
Verified13Varicella vaccine saved $5.1B in US medical costs 2007-11.
Verified14COVID vaccines saved 20 million lives in Europe first year.
Directional15Pneumococcal vaccines prevent 700,000 deaths/year globally.
Single source16Tetanus vaccine eliminated maternal/neonatal tetanus in 180 countries.
Verified17Diphtheria cases reduced 90% in Europe post-vaccination.
Verified18Rubella vaccination prevented 7.7 million CRS cases 2000-2020.
Verified19Shingles vaccine prevents 1 million cases/decade in US.
Directional20Global immunization prevents 154 million lifetime cases, 5.6M deaths 2020-2030.
Single source21Vaccines contribute $1.5 trillion to global economy yearly.
Verified22COVID vaccination reduced long COVID risk by 50% in studies.
Verified23Ebola vaccination contained 2018-2020 outbreak, no cases post-vax.
Verified24Dengue vaccine rollout reduced cases 50% in trial areas.
Directional25Smallpox vaccination economic benefit $300B globally.
Single sourcePublic Health Impact Interpretation
If you stacked all the lives saved and costs avoided by vaccines into a ledger, the column marked "humanity's best investment" would be overflowing, while the one marked "regrettable needle phobia" would look pitifully empty.
Safety
1In VAERS data analysis, anaphylaxis rate after mRNA COVID-19 vaccines was 2.5-11.1 cases per million doses for Pfizer.
Verified2Myocarditis risk after mRNA COVID-19 vaccination in males 12-29 years was 40.6 cases per million second doses (Pfizer).
Verified3Guillain-Barré Syndrome incidence after Janssen COVID-19 vaccine was 15.5 excess cases per million doses in females.
Verified4Thrombosis with Thrombocytopenia Syndrome (TTS) after J&J vaccine was 3.2 cases per million doses overall.
Directional5Serious adverse events after Pfizer COVID-19 vaccine were 0.6 per 10,000 doses in trials.
Single source6Moderna trial reported 0.6% systemic reactions grade 3+ after second dose.
Verified7AstraZeneca vaccine myopericarditis rate was 1.3 per million doses in EU data.
Verified8MMR vaccine does not cause autism; meta-analysis of 1.2 million children showed no association.
Verified9HPV vaccine serious adverse events rate is 1.7 per 100,000 doses.
Directional10Rotavirus vaccine intussusception risk is 1-6 excess cases per 100,000 vaccinated infants.
Single source11Influenza vaccine Guillain-Barré risk is less than 1 excess case per million doses.
Verified12Shingrix vaccine serious AEs were 9.4% after first dose, mostly resolved.
Verified13Pneumococcal vaccine local reactions in 20-30% of children, serious rare <1%.
Verified14Tdap vaccine pain at site in 66%, severe <1%.
Directional15Hepatitis B vaccine AEs mild, anaphylaxis 1 per 1.1 million doses.
Single source16Varicella vaccine rash in 5% after first dose, serious complications rare.
Verified17Polio OPV vaccine-associated paralytic polio 2-4 cases per million doses.
Verified18Meningococcal vaccine syncope common but transient, serious AEs 1/10,000.
Verified19COVID-19 vaccines overall SAE rate 0.0004% in 298 million doses administered.
Directional20No increased miscarriage risk with COVID-19 vaccination; 14.1% rate vs 15.6% unvaccinated.
Single source21Bell's palsy after mRNA vaccines not higher than background (3.5 per 100,000).
Verified22Transverse myelitis after AstraZeneca rare, 0.78 per million doses.
Verified23Pediatric Pfizer vaccine myocarditis 1 in 100,000 doses, mostly mild.
Verified24No vision loss signal after COVID vaccines in VAERS review.
Directional25HPV vaccine no increase in autoimmune diseases; RR 1.0 (95% CI 0.8-1.2).
Single source26Flu vaccine no association with asthma exacerbations in children.
Verified27Shingrix no increased herpes zoster risk post-vaccination.
Verified28DTaP no encephalopathy causal link; background rate.
VerifiedSafety Interpretation
While these numbers may seem daunting in isolation, together they reveal a reassuringly mundane truth: the risk of a serious vaccine side effect is like being struck by lightning while also finding a four-leaf clover—statistically possible, but profoundly unlikely, and far outweighed by the well-documented storm of dangers posed by the diseases they prevent.
Sources & References
- Reference 1NEJMnejm.orgVisit source
- Reference 2THELANCETthelancet.comVisit source
- Reference 3MEDRXIVmedrxiv.orgVisit source
- Reference 4CDCcdc.govVisit source
- Reference 5WHOwho.intVisit source
- Reference 6EMAema.europa.euVisit source
- Reference 7FDAfda.govVisit source
- Reference 8GOVgov.ukVisit source
- Reference 9ANNALSannals.orgVisit source
- Reference 10PEDIATRICSpediatrics.aappublications.orgVisit source
- Reference 11OURWORLDINDATAourworldindata.orgVisit source
- Reference 12COVID19DASHBOARDcovid19dashboard.mohfw.gov.inVisit source
- Reference 13DIGITALdigital.nhs.ukVisit source
- Reference 14IMMUNIZATIONDATAimmunizationdata.who.intVisit source
- Reference 15NCICncic.gov.auVisit source
- Reference 16HEALTH-INFOBASEhealth-infobase.canada.caVisit source
- Reference 17NCVncv.kdca.go.krVisit source
- Reference 18RKIrki.deVisit source
- Reference 19GAVIgavi.orgVisit source
- Reference 20NIIDniid.go.jpVisit source
- Reference 21DASHBOARDdashboard.covid19.gouv.frVisit source
- Reference 22GOBgob.mxVisit source
- Reference 23ENen.nhc.gov.cnVisit source
- Reference 24ISSiss.itVisit source
- Reference 25NCBIncbi.nlm.nih.govVisit source
- Reference 26ISCIIIiscIII.esVisit source
- Reference 27POLIOERADICATIONpolioeradication.orgVisit source
- Reference 28PAHOpaho.orgVisit source
- Reference 29ECDCecdc.europa.euVisit source
- Reference 30IMPERIALimperial.ac.ukVisit source
- Reference 31PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 32IFPMAifpma.orgVisit source